BARRO, C.; AFFONSO, A. A. M.; WAQUAR, A.; ARAGAO, N.; BAKHEET, A.; CAJIAO, K.; SOUZA, A. B. C.; DÍAZ, L. A. Q.; FOWLER, C. M.; HERRERA, R.; HUAPAYA, L. A. N.; KORNIENKO, K.; MAGALHÃES, A. M. V.; MENEZES, T. D. O.; MORDOJOVICH, M.-A.; NOSÉ, R.; PAN, H.; PERSIVALE, K. S.; POVEDA, C.; RAMOS, C.; RODRIGUES, M. A.; RUIZ, J. M. V.; SOARES, R.; DANGHAN, X. The INCA trial: a multicenter, randomized, phase II, open-label clinical trial to evaluate the combination therapy with Ipilimumab plus Nivolumab versus Chemotherapy (Pemetrexate-Cisplatin) in patients with Advanced non-squamous NSCLC naive to treatment. Principles and Practice of Clinical Research, v. 4, n. 1, p. 6-13, 25 Jul. 2018.